Esketamine Was Not “Cost-Effective” for Treatment-Resistant Depression in Hong Kong
Esketamine Lost the Cost-Effectiveness Race in Hong Kong TL;DR: A 5-year Hong Kong model found esketamine plus an antidepressant bought only a small quality-adjusted survival gain at US$29,061 per patient, leaving it behind cheaper third-line options like combination therapy. Key Findings Seven third-line strategies modeled: A Markov cohort model followed adults with treatment-resistant depression in …
